Published in Scientific Reports: SarcNet uses federated AI to forecast metastatic relapse in STS, achieving 0.797 AUC. Dive deeper: www.nature.com/articles/s41...

We’re releasing CytoSyn, our new diffusion model for synthetic histopathology image generation. REPA-E architecture. H0-mini conditioning. Model: huggingface.co/Owkin-Biopti... Supporting article: www.owkin.com/blogs-case-s...

Discover OKN4395 at #SITC2025—Poster #1169. A triple inhibitor overcoming tumor immunosuppression by targeting EP2, EP4, DP1. Learn more about OKN4395 at epkin.ai

Our new multimodal ML models achieve high accuracy in predicting iCCA outcomes (c-index 0.70). This collaborative study with @mskcancercenter.bsky.social enhances understanding of the disease and may guide treatment selection. Check out the paper: www.sciencedirect.com/science/arti...

We dived into cancer cell interactions with COMPOTES. Using MOSAIC data, we uncovered 45 programs across major cancers, shedding light on immune dynamics and therapeutic paths. Pre-print at: doi.org/10.1101/2025...

We used ML & multimodal data to find glioblastoma biomarkers linked to long survival. Our model (AUC 0.85), trained on @ap-hp.bsky.social data, reveals tissue regions predicting survival. Model interpretation & biological insights from MOSAIC’s GBM cohort. Pre-print: www.biorxiv.org/content/10.1...

📢 New on bioRxiv: We developed SpaMIL, a novel Multiple Instance Learning (MIL) framework for predicting patient-level outcomes from spatial transcriptomics data. Read the preprint: www.biorxiv.org/content/10.1...

K Navigator launches on May 6th - introducing the scientific literature tool, K-literature, tailored to scientific research, featuring: 📑 26.5+ million papers 🧠 Natural language input 👥 Hallucination limitation K Navigator is free to use for academic researchers. www.owkin.com/k-os/owkin-k...

🕹️ How fast can you reach K? Play the game as we get ready to launch K Navigator, a free agentic AI co-pilot boosting the productivity of biology research and breakthroughs across the world. Try it now: Google Play → play.google.com/store/apps/d... App Store → apps.apple.com/fr/app/first...

Excited to share our latest research on a novel approach for controlling the sensitivity of whole-slide image classification models in digital pathology, using the TSM (Tile Score Matching) method. Read the full pre-print: arxiv.org/abs/2502.20144

💥 Owkin K Navigator launches on the 6th of May. Our free-to-use agentic AI co-pilot for researchers across the world, to enhance the productivity of biological research and drive breakthrough discoveries. Kountdown to K begins now. Sign up here → www.owkin.com/k-os/owkin-k

We're launching a comprehensive multimodal patient data discovery program with 20 leading healthcare institutions across France, Spain, Germany, Italy, the US, the UK, and Israel to accelerate medical research by breaking down data silos. Read more at → www.owkin.com/newsfeed/owk...

Join us for a webinar, co-hosted with @owkin.bsky.social, on "Harnessing spatial biology & AI to develop targeted therapeutic strategies." Learn how Owkin is using spatial & AI to optimize development of antibody-drug conjugate strategies & generate novel hypotheses: bit.ly/4jVbQZr

After an eventful #AIActionSummit, our SVP, Head of Public Affairs & Impact Yedidia Levy-Zauberman unpacks Owkin’s key moments in our latest blog - from a high-impact glioblastoma hackathon to recognition by President Emmanuel Macron. 📕 Read the blog → www.owkin.com/blogs-case-s...

A comprehensive evaluation of histopathology foundation models for ovarian cancer subtype classification www.nature.com/articles/s41... @owkin.bsky.social

Can AI help Pharma speed up drug development? World Street Journal features our CEO Thomas Clozel alongside Aviv Regev from Genentech, AstraZeneca's Chief Data Scientist Jim Weatherall, and GSK's Senior Director of ML and AI Patrick Schwab. 📰 Read the WSJ article → www.wsj.com/tech/ai/phar...

Owkin in the news 👀 Emmanuelle Macron references Owkin’s work, speaking on France’s AI boom 💥 for the #AIActionSummit. Les Echos dives deeper into Owkin’s mission to redefine healthcare through AI: “AI in healthcare - France’s trump card”. Read more here → www.lesechos.fr/start-up/eco...

Le Figaro features our CEO, Thomas Clozel, as one of the top seven French ⭐️s in the AI industry alongside @yann-lecun.bsky.social, Jérôme Pesenti - Owkin board member - and Luc Julia, creator of Apple’s Siri. 👀 Read the article → www.lefigaro.fr/secteur/high...

📢 4 hours in, 100s of lines of code already written, our Glioblastoma moonshot hackathon is off with a bang. 💥 Learn more at: www.owkin.com/connect/glio... #GBM #Hackathon

3 days to go until 100 experts meet at Palais Brongniart, Paris, for our AI Moonshot Hackathon in Glioblastoma Research! Sponsored by Servier and Owkin, with support from AWS, 10x Genomics, Bioptimus, and La Place Fintech. Learn more: www.owkin.com/connect/glio... #gbm #neuroskyence #spatialomics

We’re excited to announce the first patient has been dosed in our Phase 1 clinical trial of OKN4395, a first-in-class EP2/EP4/DP1 triple inhibitor for solid tumors⁠. Learn more in STAT’s latest interview with Andrew Pierce, Owkin’s SVP Discovery & Development: www.statnews.com/2025/01/30/o...

Check out our explainer video to see how our new AI model predicts YAP1/TEAD activity directly from routine H&E-stained histology slides. Watch the video: vimeo.com/1035641635?s... #pathsky #aisky #medai